Stem definition | Drug id | CAS RN |
---|---|---|
1214 | 2746-81-8 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
March 15, 1967 | FDA | APOTHECON |
None
None
None
None
Source | Code | Description |
---|---|---|
FDA CS | M0016525 | Phenothiazines |
CHEBI has role | CHEBI:37930 | phenothiazine antipsychotic drugs |
CHEBI has role | CHEBI:48561 | dopaminergic antagonists |
CHEBI has role | CHEBI:149553 | anticoronaviral drug |
MeSH PA | D014150 | Antipsychotic Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D011619 | Psychotropic Drugs |
MeSH PA | D014149 | Tranquilizing Agents |
MeSH PA | D015259 | Dopamine Agents |
MeSH PA | D018492 | Dopamine Antagonists |
MeSH PA | D018377 | Neurotransmitter Agents |
FDA EPC | N0000175746 | Phenothiazine |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Schizophrenia | indication | 58214004 | DOID:5419 |
Psychotic disorder | indication | 69322001 | |
Alcoholism | contraindication | 7200002 | |
Organophosphate poisoning | contraindication | 8260003 | |
Weight gain finding | contraindication | 8943002 | |
Neuroleptic malignant syndrome | contraindication | 15244003 | DOID:14464 |
Senile dementia | contraindication | 15662003 | |
Chronic disease of respiratory system | contraindication | 17097001 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Glaucoma | contraindication | 23986001 | DOID:1686 |
Orthostatic hypotension | contraindication | 28651003 | |
Torsades de pointes | contraindication | 31722008 | |
Parkinsonism | contraindication | 32798002 | |
Conduction disorder of the heart | contraindication | 44808001 | |
Chronic heart failure | contraindication | 48447003 | |
Bradycardia | contraindication | 48867003 | |
Extrapyramidal disease | contraindication | 76349003 | |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Leukopenia | contraindication | 84828003 | DOID:615 |
Stupor | contraindication | 89458003 | |
Tardive dyskinesia | contraindication | 102449007 | |
Prolonged QT interval | contraindication | 111975006 | |
Acute disease of cardiovascular system | contraindication | 128487001 | |
Angina pectoris | contraindication | 194828000 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Metabolic syndrome X | contraindication | 237602007 | DOID:14221 |
Hyperprolactinemia | contraindication | 237662005 | DOID:12700 |
Benign prostatic hyperplasia | contraindication | 266569009 | |
Retention of urine | contraindication | 267064002 | |
Anemia | contraindication | 271737000 | DOID:2355 |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Coma | contraindication | 371632003 | |
At risk for aspiration | contraindication | 371736008 | |
Visual impairment | contraindication | 397540003 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
Obesity | contraindication | 414916001 | DOID:9970 |
Congenital long QT syndrome | contraindication | 442917000 | |
Carcinoma of female breast | contraindication | 447782002 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.85 | Basic |
pKa2 | 3.85 | Basic |
pKa3 | 2.72 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
D(2) dopamine receptor | GPCR | ANTAGONIST | Ki | 9.27 | PDSP | CHEMBL | |||
Alpha-2A adrenergic receptor | GPCR | Ki | 6.50 | PDSP | |||||
Sodium-dependent serotonin transporter | Transporter | Ki | 5.23 | PDSP | |||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 6.84 | PDSP | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 7.98 | PDSP | |||||
5-hydroxytryptamine receptor 2C | GPCR | Ki | 6.05 | PDSP | |||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 7.42 | PDSP | |||||
5-hydroxytryptamine receptor 7 | GPCR | Ki | 8.10 | PDSP | |||||
Alpha-1A adrenergic receptor | GPCR | Ki | 8.19 | PDSP | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 7.09 | PDSP | |||||
D(3) dopamine receptor | GPCR | Ki | 9.61 | PDSP | |||||
D(1B) dopamine receptor | GPCR | Ki | 7.89 | PDSP | |||||
Histamine H1 receptor | GPCR | Ki | 7.68 | PDSP | |||||
Histamine H2 receptor | GPCR | Ki | 6.25 | PDSP | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 5.96 | PDSP | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 5.15 | PDSP | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 5.84 | PDSP | |||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 5.27 | PDSP | |||||
Muscarinic acetylcholine receptor M5 | GPCR | Ki | 6.45 | PDSP | |||||
5-hydroxytryptamine receptor 1B | GPCR | Ki | 6.48 | PDSP | |||||
5-hydroxytryptamine receptor 1D | GPCR | Ki | 6.48 | PDSP | |||||
Alpha-2C adrenergic receptor | GPCR | Ki | 7.54 | PDSP | |||||
D(4) dopamine receptor | GPCR | Ki | 7.44 | PDSP | |||||
Alpha-1B adrenergic receptor | GPCR | Ki | 7.89 | PDSP | |||||
5-hydroxytryptamine receptor 5A | GPCR | Ki | 6.84 | PDSP | |||||
D(1A) dopamine receptor | GPCR | Ki | 7.68 | PDSP | |||||
5-hydroxytryptamine receptor 1E | GPCR | Ki | 6.27 | PDSP |
ID | Source |
---|---|
4017724 | VUID |
N0000179195 | NUI |
D00792 | KEGG_DRUG |
4017724 | VANDF |
4019762 | VANDF |
C0066682 | UMLSCUI |
CHEBI:5125 | CHEBI |
CHEBI:5123 | CHEBI |
CHEMBL1200951 | ChEMBL_ID |
C017610 | MESH_SUPPLEMENTAL_RECORD_UI |
QSB34YF0W9 | UNII |
3389 | PUBCHEM_CID |
DB00623 | DRUGBANK_ID |
30129 | RXNORM |
3882 | MMSL |
4749 | MMSL |
d00237 | MMSL |
001473 | NDDF |
001475 | NDDF |
111125005 | SNOMEDCT_US |
372730004 | SNOMEDCT_US |
41365009 | SNOMEDCT_US |
C0016368 | UMLSCUI |
946 | INN_ID |
3372 | PUBCHEM_CID |
D005476 | MESH_DESCRIPTOR_UI |
None